Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. AI Tech Top10 & U.S. High Dividend 3070 Index (AUTUD37)
3/23/2026, 12:00:00 AM
Pfizer and Valneva announced positive topline results from the Phase 3 trial of their Lyme disease vaccine candidate (PF-07307405), showing over 70% efficacy. Pfizer plans to submit for regulatory approval in 2026. Medium importance estimated due to positive Phase 3 results for a key vaccine candidate.
Korean Translation
화이자와 발네바, 라임병 백신 후보물질(PF-07307405)의 3상 임상시험에서 70% 이상의 효능을 보인 긍정적인 탑라인 결과를 발표함. 2026년 규제 당국에 승인을 신청할 계획임. 주요 백신 후보물질의 3상 성공으로 인해 중간 중요도로 예상됨.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
Murphy Oil Corp (MUR) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
First quarter 2026 earnings release expected; analysts forecast revenue of $9.83B and EPS of $1.18-$1.27 forecasted.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's first-quarter 2026 earnings release is scheduled. Low importance estimated as a routine scheduled earnings announcement.
5/5/2026, 12:00:00 AM
T. Rowe Price Group Inc (TROW) · Earnings Release
First quarter 2026 earnings release on 2026-05-01, estimated based on financial news outlets. Earnings releases typically impact price by at least 5%, scheduled.
5/1/2026, 12:00:00 AM
Antero Midstream Corp (AM) · Earnings Release
First quarter 2026 earnings release is scheduled.
4/29/2026, 12:00:00 AM